$1.45
3.57% yesterday
Nasdaq, May 20, 10:12 pm CET
ISIN
US92023M1018
Symbol
GRI
Sector
Industry

Vallon Pharmaceuticals Inc Stock price

$1.45
-0.01 0.68% 1M
-9.41 86.65% 6M
-12.63 89.70% YTD
-93.58 98.47% 1Y
-25,858.20 99.99% 3Y
-349,001.75 100.00% 5Y
-349,001.75 100.00% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.05 3.57%
ISIN
US92023M1018
Symbol
GRI
Sector
Industry

Key metrics

Market capitalization $3.11m
Enterprise Value $-60.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.01
P/B ratio (TTM) P/B ratio 0.63
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-9.39m
Free Cash Flow (TTM) Free Cash Flow $-8.14m
Cash position $3.28m
EPS (TTM) EPS $-108.12
Short interest 14.88%
Show more

Is Vallon Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Vallon Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Vallon Pharmaceuticals Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Vallon Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Vallon Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.91 4.91
40% 40%
-
- Research and Development Expense 4.48 4.48
11% 11%
-
-9.39 -9.39
24% 24%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.39 -9.39
24% 24%
-
Net Profit -9.37 -9.37
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vallon Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vallon Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
5 days ago
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21 st at 2:40 PM ET
Neutral
GlobeNewsWire
6 days ago
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Neutral
GlobeNewsWire
13 days ago
The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed
More Vallon Pharmaceuticals Inc News

Company Profile

Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO W. Hertz
Employees 4
Founded 2009
Website www.gribio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today